Why in News?
CAR T-cell Therapy (Chimeric Antigen Receptor T-cell therapy) is recently in the news because of a major breakthrough in accessibility and affordability in India, specifically the successful widespread rollout of the indigenous NexCAR19 therapy.
What is CAR T-Cell Therapy?
- It is a type of Immunotherapy that "reprograms" a patient’s own immune system to fight cancer.
- Living Drug: Unlike traditional pills or chemicals, it uses the patient’s own T-cells (white blood cells).
- Gene Engineering: T-cells are extracted and genetically modified in a lab to produce Chimeric Antigen Receptors (CARs) on their surface.
- Targeting: These receptors act like a "GPS," allowing the T-cells to identify and bind to specific proteins (like CD19) on cancer cells.
- The Kill: Once infused back into the patient, the cells multiply and systematically destroy the tumour cells.
The Process (Step-by-Step)
- Leukapheresis: Blood is drawn to collect T-cells; the rest of the blood is returned to the body.
- Engineering: Scientists insert a gene for the "CAR" into the T-cells using a viral vector.
- Expansion: The new CAR T-cells are grown in large numbers in a laboratory.
- Conditioning: The patient receives mild chemotherapy to make "room" for the new cells.
- Infusion: The engineered cells are dripped back into the patient’s bloodstream.
Benefits & Applications
- One-Time Treatment: Unlike chemotherapy which requires multiple rounds, this is often a single infusion.
- High Remission Rates: Effective for patients who have "relapsed" (cancer came back) or are "refractory" (did not respond to other treatments).
- Current Approvals: Primarily used for:
- B-cell Acute Lymphoblastic Leukemia (ALL)
- B-cell Lymphomas
- Multiple Myeloma
Challenges & Side Effects
- Cytokine Release Syndrome (CRS): An overreaction of the immune system that can cause high fever and low blood pressure.
- Neurotoxicity: Temporary confusion, tremors, or difficulty speaking.
- High Cost: Despite Indian versions being cheaper, it remains expensive for many due to the complex lab infrastructure required.
- Targeting Solid Tumours: It is currently less effective against solid tumours (like lung or breast cancer) due to the "hostile" environment around the tumour.
The "Indian Advantage"
The NexCAR19 therapy, developed by ImmunoACT (an IIT Bombay incubated company), is unique because it uses a "humanized" version of the receptor, which reportedly leads to lower toxicity (fewer side effects) compared to Western versions.
Download Pdf
